The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: Extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds

Health Technology Assessment

Volumn 18, Issue 23, 2014, Pages 1-195

  Kitchener, Henry C ^a   Canfell, Karen ^b,c   Gilham, Clare ^d   Sargent, Alexandra ^e   Roberts, Chris ^f   Desai, Mina ^e   Peto, Julian ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CANCER RESEARCH DIVISION   (Australia)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER GRADING; CLINICAL EFFECTIVENESS; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTODIAGNOSIS; DYSKARYOSIS; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INCIDENCE; LIQUID BASED CYTOLOGY; PAPILLOMAVIRUS INFECTION; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; SCREENING; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; AGE DISTRIBUTION; AGED; CAUSE OF DEATH; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH SERVICE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STANDARDS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COST-BENEFIT ANALYSIS; ENGLAND; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INCIDENCE; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; STATE MEDICINE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84900315671     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18230     Document Type: Article

References (69)

1. Kitchener HC, Almonte M, Dowie R, Stoykova B, Sargent A, Roberts C, et al. ARTISTIC: a randomised trial of HPV testing in primary cervical screening. Health Technol Assess 2009; 13(51).
2. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82. http://dx. doi. org/10. 1016/S1470-2045(09)70156-1.
3. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61. http://dx. doi. org/10. 1038/sj. bjc. 6603210.
4. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008; 98: 1704-9. http://dx. doi. org/10. 1038/sj. bjc. 6604324.
5. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer 2008; 18: 743-8.
6. Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010; 48: 554-8. http://dx. doi. org/10. 1128/JCM. 00896-09.
7. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72. http://dx. doi. org/10. 1016/S0140-6736(07)61450-0.
8. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97. http://dx. doi. org/10. 1056/NEJMoa073204.
9. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57. http://dx. doi. org/10. 1016/S1470-2045(09)70360-2.
10. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769. http://dx. doi. org/10. 1136/bmj. a769.
11. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754. http://dx. doi. org/10. 1136/bmj. a1754.
12. Moss S, Kelly R, Legood R, Sadique Z, Canfell K, Lew JB, et al. Evaluation of Sentinel Sites for HPV Triage and Test of Cure: Report to NHS Cancer Screening Programmes. 2011. URL: www. cancerscreening. nhs. uk/cervical/hpv-sentinel-sites. html (accessed 2 July 2013).
13. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14. http://dx. doi. org/10. 1016/S0140-6736(09)61248-4.
14. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978; 31: 557-60. http://dx. doi. org/10. 1016/0021-9681(78)90043-7.
15. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 2010; 10: 734. http://dx. doi. org/10. 1186/1471-2458-10-734.
16. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aus 2006; 185: 482-6.
17. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004; 91: 530-6. http://dx. doi. org/10. 1038/sj. bjc. 6602002.
18. Medical Services Advisory Committee. Automation Assisted and Liquid Based Cytology for Cervical Cancer Screening. Canberra, ACT: Medical Services Advisory Committee; 2009.
19. Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, et al. MAVARIC-a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess 2011; 15(3).
20. Medical Services Advisory Committee. Human Papillomavirus Triage Test For Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions. Canberra, ACT: Medical Services Advisory Committee; 2009. URL: www. health. gov. au/internet/msac/.../39_MSAC_Assessment_Report. pdf (last accessed 30 January 2014).
21. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011; 29: 2487-94. http://dx. doi. org/10. 1016/j. vaccine. 2010. 12. 085.
22. Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 2011; 11: 239. http://dx. doi. org/10. 1186/1471-2407-11-239.
23. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-42. http://dx. doi. org/10. 1016/S0140-6736(01)06883-0.
24. Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. MMWR Morb Mortal Wkly Rep 2009; 59: 1018-23.
25. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH, et al. Sexual behaviour in Britain: early heterosexual experience. Lancet 2001; 358: 1843-50. http://dx. doi. org/10. 1016/S0140-6736(01)06885-4.
26. Joseph L. Bayesian Data Analysis. 2nd edn. Boca Raton, FL: Chapman & Hall/CRC; 2004.
27. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2008. URL: www. nice. org. uk/aboutnice/howwework/devnicetech/GuideToMethodsTechnologyAppraisal2008. jsp (last accessed 2 July 2013).
28. Legood R, Smith M, Lew JB, Walker R, Moss S, Kitchener H, et al. Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ 2012; 345: e7086. http://dx. doi. org/10. 1136/bmj. e7086.
29. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6. http://dx. doi. org/10. 1016/S0140-6736(03)14955-0.
30. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology-a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-77. http://dx. doi. org/10. 1097/01. AOG. 0000296488. 85807. b3.
31. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101. http://dx. doi. org/10. 1002/ijc. 21955.
32. Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135: 468-75. http://dx. doi. org/10. 1309/AJCPZ5JY6FCVNMOT.
33. Cervical Screening Programme England 2007-08. Data Tables: The Health and Social Care Information Centre. 2008. URL: www. cancerscreening. nhs. uk/cervical/hpv-sentinel-sites. html (accessed 2 July 2013).
34. Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener H, et al. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006; 332: 83-5. http://dx. doi. org/10. 1136/bmj. 38701. 440961. 7C.
35. Martin-Hirsch P, Rash B, Martin A, Standaert B. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales. BJOG 2007; 114: 408-15. http://dx. doi. org/10. 1111/j. 1471-0528. 2007. 01261. x.
36. Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004; 91: 84-91. http://dx. doi. org/10. 1038/sj. bjc. 6601884.
37. Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: PSSRU, University of Kent; 2010.
38. Simonella LM. Characterisation and Assessment of Organised Screening, Model Validation, and Health State Preference Scores in Decision Analytic Models of Human Papillomavirus (HPV) Vaccination in Australia and New Zealand. PhD Thesis. Sydney, NSW: University of Sydney; 2012.
39. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41. http://dx. doi. org/10. 3201/eid1301. 060438.
40. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15. http://dx. doi. org/10. 1093/jnci/djh104.
41. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007; 27: 414-22. http://dx. doi. org/10. 1177/0272989X07302128.
42. Department of Health. Annual HPV Vaccine Coverage in England 2010/2011. London: Department of Health; 2012.
43. Cancer Research UK. Cervical Cancer-UK Mortality Statistics. London: Cancer Research UK. URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/cervix/mortality/uk-cervical-cancermortality-statistics (last accessed 12 June 2010).
44. Office for National Statistics. Interim Life Tables for England 2005-2007 (Females). Office for National Statistics; 2009. URL: www. statistics. gov. uk/downloads/theme_population/Interim_Life/ILTEng0608Reg. xls (last accessed 14 December 2009).
45. Redburn JC, Murphy MF. Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales. BJOG 2001; 108: 388-95. http://dx. doi. org/10. 1016/S0306-5456(00)00098-X.
46. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10. http://dx. doi. org/10. 1016/S1470-2045(11)70287-X.
47. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 781-9.
48. Office for National Statistics. 2011 Census-Population and Household Estimates for England and Wales. London: Office for National Statistics; 2011.
49. Office for National Statistics. Cancer Registrations in England, 2010 (data table). London: Office for National Statistics; 2010.
50. International Agency for Research on Cancer and International Association of Cancer Registries. Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer 2007.
51. West Midlands Cancer Intelligence Unit. Cervical Cancer Survival Data. Birmingham: West Midlands Cancer Intelligence Unit; 2009.
52. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJD, Lozano R, Inoue M. Age Standardization of Rates: a New WHO Standard. World Health Organization; 2001. URL: www. who. int/healthinfo/paper31. pdf (last accessed 2 July 2013).
53. Rudmik L, Drummond M. Health economic evaluation: Important principles and methodology. Laryngoscope 2013; 123: 1341-7. http://dx. doi. org/10. 1002/lary. 23943.
54. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9. http://dx. doi. org/10. 1093/jnci/dji187.
55. Moss S, Bailey A, Sargent A, Cubie H, Denton K, Ellis D, et al. Results for the NHSCSP Multiple HPV Testing Study. Poster presentation at 28th International Papillomavirus Conference, Puerto Rico, 2012.
56. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012; 119: 699-709. http://dx. doi. org/10. 1111/j. 1471-0528. 2011. 03228. x.
57. Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany-a decision analysis. Eur J Cancer 2011; 47: 1633-46. http://dx. doi. org/10. 1016/j. ejca. 2011. 03. 006.
58. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 2012; 106: 1571-8. http://dx. doi. org/10. 1038/bjc. 2012. 94.
59. Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Can J Public Health 2010; 101: 220-5.
60. Franco E. Is type replacement something to worry about: yes or no? Oral presentation at EUROGIN 2010, Monte Carlo, Monaco, 2010.
61. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1), No. 32. 2001. URL: www. ons. gov. uk/ons/publications/re-reference-tables. html?edition=tcm%3A77-156486 (last accessed 14 December 2009).
62. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow-up in the ARTISTIC trial. Eur J Cancer 2011; 47: 864-71. http://dx. doi. org/10. 1016/j. ejca. 2011. 01. 008.
63. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24(Suppl. 3): S78-89 http://dx. doi. org/10. 1016/j. vaccine. 2006. 05. 117.
64. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008; 115: 1001-7. http://dx. doi. org/10. 1111/j. 1471-0528. 2008. 01748. x.
65. Moss SM, Gray A, Marteau T, Legood R, Henstock E, Maissi E. Evaluation of HPV/LBC Cervical Screening Pilot Studies. Report to the Department of Health (revised October 2004). Sutton: Institute of Cancer Research; 2004.
66. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012; 344: e670. http://dx. doi. org/10. 1136/bmj. e670.
67. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the human papillomavirus vaccination in the United Kingdom. Vaccine 2010; 28: 4091-102. http://dx. doi. org/10. 1016/j. vaccine. 2009. 09. 125.
68. Caro JJ, Briggs A, Siebert U, Kuntz K. Modelling good research practices-overview: a report of the ISPOR-SMDM Modelling Good Research Practices Task Force-1. Med Decis Making 2012; 32: 667-77. http://dx. doi. org/10. 1177/0272989X12454577.
69. Drummond M. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.